2-Methoxy-5-[(Z)-2-(4-methoxy-benzofuran-6-yl)-ethenyl]-phenol

ID: ALA511529

Chembl Id: CHEMBL511529

PubChem CID: 25130865

Max Phase: Preclinical

Molecular Formula: C18H16O4

Molecular Weight: 296.32

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(/C=C\c2cc(OC)c3ccoc3c2)cc1O

Standard InChI:  InChI=1S/C18H16O4/c1-20-16-6-5-12(9-15(16)19)3-4-13-10-17(21-2)14-7-8-22-18(14)11-13/h3-11,19H,1-2H3/b4-3-

Standard InChI Key:  WKTSRPYICDVYET-ARJAWSKDSA-N

Associated Targets(Human)

HT-29 (80576 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H460 (60772 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

BMEC (52 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 296.32Molecular Weight (Monoisotopic): 296.1049AlogP: 4.33#Rotatable Bonds: 4
Polar Surface Area: 51.83Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 9.84CX Basic pKa: CX LogP: 3.85CX LogD: 3.85
Aromatic Rings: 3Heavy Atoms: 22QED Weighted: 0.73Np Likeness Score: 0.87

References

1. Simoni D, Romagnoli R, Baruchello R, Rondanin R, Grisolia G, Eleopra M, Rizzi M, Tolomeo M, Giannini G, Alloatti D, Castorina M, Marcellini M, Pisano C..  (2008)  Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.,  51  (19): [PMID:18783207] [10.1021/jm8005004]

Source